Short- and Medium-term Results of New Generation Aortic

Short- and Medium-term Outcomes of New Generation Biological Aortic Valves in Aortic Valve Replacement Surgery

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05055089

Acronym

RVANG

Enrollment

172

Registered

2021-09-23

Start date

2021-09-06

Completion date

2022-03-06

Last updated

2026-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Valve, Cardiac Surgery, Echocardiography, Mortality

Keywords

Echocardiography, Aortic valve, New-generation bioprosthesis, Conventional bioprosthesis, Rapid-deployment bioprosthesis, Sutureless valves, Function prostheses, Cardiac Surgery, Mortality

Brief summary

Over the past decade, aortic valve replacement surgery has undergone significant changes in terms of both the approaches and the prostheses used. In parallel with the historical biological prostheses for aortic valve surgery, a new generation of bioprostheses has been marketed since 2008, with the entry of these new prostheses in the armatorium of the Amiens-Picardy University Hospital since 2010. These are rapid deployment prostheses or prostheses without sutures. As a result, patients undergoing aortic valve replacement have been able to benefit from this type of bioprosthesis during their procedures. There are few publications reporting the 5-year follow-up of these bioprostheses. The investigators therefore decided to follow up patients operated on by a new generation bioprosthesis to study the 5-year survival and the functioning of their bioprostheses, in order to make a scientific contribution to the follow-up of these valves. These patients will be compared to patients who have benefited from the implantation of traditional bioprostheses.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Retrospectively included all patients examined since 2010. * Patients who have aortic valve surgery from the Cardiac Surgery Department of the University Hospital of Amiens.

Exclusion criteria

* Refusal to participate in the patient. * Patients who have previously had aortic valve surgery.

Design outcomes

Primary

Measure	Time frame	Description
Variation of mortality rate between both groups	3 months	both groups are : * Patients undergoing surgical aortic valve replacement with new-generation bioprostheses * Patients who received a traditional bioprosthesis

Countries

France

Outcome results